MELD Score
iatroX editorial team · Updated · Record checked · editorial policy
MELD estimates 3-month mortality risk in patients with end-stage liver disease using serum creatinine, bilirubin, and INR. It is the primary score used for organ allocation in liver transplantation (UNOS/Eurotransplant).
inputs
evidence
derivation
Originally developed by Malinchoc et al. (2000) to predict mortality after TIPS placement. Adapted by Kamath et al. (2001) for general cirrhosis mortality prediction. Adopted by UNOS for liver transplant allocation in 2002.
validation
MELD has a c-statistic of 0.83–0.87 for 3-month mortality prediction in cirrhosis. Validated across multiple international cohorts. Superior to Child-Pugh for short-term mortality prediction due to use of continuous, objective variables.
guideline endorsements
Original MELD entered US liver allocation in 2002, followed by MELD-Na in 2016 and MELD 3.0 in July 2023. Use current transplant-centre policy for allocation decisions.
references
- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470.PMID: 11172350
- Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91-96.PMID: 12512033
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.PMID: 29653741
- Supporting guidance — hrsa.gov (checked 14 November 2026).link ↗